LACO-Stim® Technology of UTC Therapeutics Takes Global Center Stage Again – Oral Presentation at 2026 ASGCT Annual Meeting Unveils New CAR-T Breakthroughs for Solid Tumors

Hot on the heels of two core CAR-T research achievements being selected for the 2026 American Association for Cancer Research (AACR) Annual Meeting, UTC Therapeutics Inc., a pioneer in China’s solid tumor immunotherapy, announces another remarkable milestone! Research findings based on the company’s proprietary LACO-Stim® technology have been accepted as an oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, set to showcase China’s original technological breakthroughs in CAR-T therapy for solid tumors at this world-renowned flagship conference in gene and cell therapy.

The 2026 ASGCT Annual Meeting will be held in Boston, USA, from May 11 to 15. As the most authoritative academic gathering in the global gene and cell therapy field, it will bring together preeminent scientists, clinicians and industry leaders worldwide. Dr. Yangbing Zhao, a globally distinguished leader in T cell engineering and cancer immunotherapy, President and Chief Scientific Officer of UTC Therapeutics Inc., will deliver an oral presentation entitled Boosting the Therapeutic Effect of CAR-T Cells for Solid Tumors by Providing a Dual Functional Chimeric Co-stimulatory Molecule LACO-Stim at the conference. This marks the second time the company’s LACO-Stim® technology platform has featured at a top-tier international academic event, following its upcoming presentation at the AACR Annual Meeting.

As the flagship technology platform of UTC Therapeutics Inc., LACO-Stim® is the core highlight of this presentation. Its engineered dual-functional co-stimulatory molecule addresses the fundamental limitations of traditional CAR-T therapy for solid tumors with a groundbreaking solution. The technology not only markedly enhances the proliferation, in vivo persistence and tumor infiltration capacity of CAR-T cells, but also effectively recruits and activates antigen-presenting cells, drives epitope spreading and elicits endogenous T cell responses. This forms a self-sustaining immune amplification cycle, enabling CAR-T cells to retain potent cytotoxic activity even in the immunosuppressive tumor microenvironment of solid malignancies, thus offering an innovative therapeutic approach for solid tumor CAR-T treatment.

The acceptance of this research as an oral presentation at the ASGCT Annual Meeting stands as a testament to the global gene and cell therapy community’s high recognition of UTC’s technological innovations in CAR-T co-stimulatory molecule engineering and solid tumor therapy. Prior to this, the company’s two LACO-Stim® Armored CAR-T products targeting MSLN and CD70 were selected for the 2026 AACR Annual Meeting. The back-to-back selections at both AACR and ASGCT – two of the most prestigious international conferences in the oncology and cell therapy fields – validate the scientific rigor and clinical value of UTC Therapeutics Inc.’s core technology platform on the global stage, and underscore the international competitiveness of China’s indigenous innovations in the solid tumor CAR-T track.

UTC Therapeutics Inc has long been deeply committed to the research and development of cellular immunotherapy, building a comprehensive matrix of seven technology platforms anchored by LACO-Stim®. The company has also established a fully integrated value chain covering R&D, manufacturing, clinical development and commercialization, with dual IND approvals in China and the United States, as well as cGMP-compliant international production facilities. The consecutive showcase at two top international academic conferences is a tangible demonstration of the company’s robust technological strength and outstanding R&D capabilities. Going forward, UTC Therapeutics Inc will continue to drive product development through original technological innovation, break through the technical bottlenecks in solid tumor treatment, and deliver safer and more effective innovative therapies to address unmet clinical needs. The company is dedicated to bringing new hope for survival to cancer patients worldwide and advancing China’s innovative cellular therapy technologies onto the global stage.